RXRX RECURSION PHARMACEUTICALS, INC.
FY2025 10-K
RECURSION PHARMACEUTICALS, INC. (RXRX) filed its fiscal year 2025 10-K annual report with the SEC on Feb 25, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: AI-native drug discovery platform integrating biology, chemistry, clinical development to accelerate novel medicine creation
- • New emphasis: Clinical validation of Recursion OS in 2025 with positive Phase 1b/2 data for REC-4881 in familial adenomatous polyposis (FAP)
Management Discussion & Analysis
- • Revenue $74.7M in 2025, up 27% YoY from $58.8M driven by Sanofi partnership; 2024 revenue rose 32% from $44.6M primarily from Roche partnership
- • Operating margin negative 868% (loss $648.1M on revenue $74.7M) worsening from 815% in 2024 (loss $479.0M on $58.8M revenue)
Risk Factors
- • FDA regulatory approval risk for all drug candidates currently in discovery or clinical stages, no products approved or commercial revenue as of 2026
- • Geopolitical risk from potential U.S. and foreign regulatory reviews on foreign investments, possibly limiting strategic alliances with international partners
Get deeper insights on RECURSION PHARMACEUTICALS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.